Serum M2BPGi level is a novel predictive biomarker for the responses to pegylated interferon-α treatment in HBeAg-positive chronic hepatitis B patients-Reference-Cited by-同舟云学术

Serum M2BPGi level is a novel predictive biomarker for the responses to pegylated interferon-α treatment in HBeAg-positive chronic hepatitis B patients

Published:2018-01-12 Issue:4 Volume:90 Page:721-729
ISSN:0146-6615
Container-title:Journal of Medical Virology
language:en
Short-container-title:J Med Virol

Author:

Zhu Ming-Yu¹,Chen Pei-Zhan²,Li Jing³,Yu De-Min¹,Huang Dao¹,Zhu Xue-Juan¹,Han Yue¹,Chen Jie¹,Huang Wei¹,Chen Yong-Yan¹,Gong Qi-Ming⁴,Jiang Jie-Hong¹,Zhang Dong-Hua¹,Zhang Yan⁵,Zhang Ji-Ming³,Zhang Xin-Xin¹²^ORCID

Affiliation:

1. Clinical Virology Research Laboratory, Ruijin Hospital; School of Medicine; Shanghai Jiao Tong University; Shanghai China

2. Translational Medicine Research Center, Ruijin Hospital North, School of Medicine; Shanghai Jiao Tong University; Shanghai China

3. Department of Infectious Diseases, Huashan Hospital; Fudan University; Shanghai China

4. Department of Infectious Diseases, Institute of Infectious and Respiratory Diseases, Ruijin Hospital; School of Medicine Shanghai Jiao Tong University; Shanghai China

5. Ministry of Education Key Laboratory of Systems Biomedicine, Shanghai Center for Systems Biomedicine; Shanghai Jiao Tong University; Shanghai China

Funder

Major national science and technology special projects during the Twelfth Five-year Plan Period

Shanghai International Science and Technology Cooperation Program of China

New frontier technology joint research project of Shanghai Shen Kang Hospital Development Center

International Science & Technology Cooperation Program of China

Shanghai Jiao Tong University Interdiscipline with Medicine Program

Publisher

Wiley

Subject

Infectious Diseases,Virology

Reference40 articles.

1. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update;Liaw;Hepatol Int,2012